Genotoxicity profiling shows CRISPR effects vary

A Cell Stem Cell paper published online on May 13 reported that genotoxicity from therapeutic gene editing changed depending on both the editing platform and the cell type being tested. The study, led by Lei Lei and colleagues, examined cytosine base editing and CRISPR-Cas9 in a mouse model of familial hemophagocytic lymphohistiocytosis type 3, or FHL3, and paired the therapeutic work with a comparative safety analysis. The authors said their results showed no single safety readout captured risk across all systems. They concluded that safety testing should be tailored to the editing approach and cellular context being used. The paper’s disease model was the Jinx mouse, which carries a cryptic splice-site mutation in the Unc13d locus linked to FHL3, according to the article abstract and a university press release about the work. In that setting, the researchers used cytosine base editing to disrupt the aberrant splice site and restore immune function in the model. The same study then compared unintended effects produced by different editing systems, rather than treating efficacy and safety as separate questions. (cell.com) ### What did the researchers actually compare? The Cell Stem Cell summary said the team found “pronounced platform- and cell type-specific differences in off-target genotoxicity.” ScienceDirect’s abstract description was more specific: comparative profiling showed that a hyperactive cytosine base editor induced broader off-target activity and more structural variants than CRISPR-Cas9 in the tested system. The authors also reported that off-target sequence edits persisted, while the stability of base-editor-induced chromosomal translocations differed between cell types. (cell.com) Those findings matter because “genotoxicity” in this context is not limited to one kind of unwanted change. The study tracked sequence-level off-target edits, structural variants and chromosomal translocations, indicating that different tools can produce different classes of risk and that those risks do not behave the same way in every cell background. That is why the paper framed the results as profiling across platforms and cell types, not as a single pass-fail safety test. (cell.com) ### Why does the cell type change the result? ScienceDirect’s abstract said the stability of cytosine-base-editor-induced chromosomal translocations differed between cell types. That means the same editing platform did not generate identical downstream outcomes in every cellular setting the group examined. The paper therefore linked risk not only to the nuclease or base editor chosen, but also to the biological context in which the edit was made. (sciencedirect.com) Toni Cathomen, quoted in a press release on the study, said “The safety of genome editing methods must always be evaluated within the specific clinical context.” That statement matched the paper’s central conclusion that safety assessment should be context-specific rather than generalized from one platform or cell type to another. (sciencedirect.com) ### Does this mean base editing is always riskier than CRISPR-Cas9? The paper did not support a blanket ranking across all uses. The reported result was narrower: in the tested comparison, a hyperactive cytosine base editor showed broader off-target activity and more structural variants than CRISPR-Cas9. The same article and related summaries stressed that the observed effects were platform-specific and cell-type-specific, which limits how far the comparison can be generalized beyond the experimental systems studied. (gesundheitsindustrie-bw.de) That distinction is important because newer editing approaches are often discussed as if avoiding double-strand breaks automatically resolves safety concerns. This study adds to evidence that alternative editors can reduce some risks while introducing others that need separate measurement. The authors’ recommendation was not to abandon a platform, but to match assessment methods to the tool and tissue under study. (sciencedirect.com) ### What should readers take from this now? The paper’s practical message was that therapeutic genome editing needs tailored safety assays. Cell Stem Cell’s summary said the findings “underscore the importance of context-specific safety profiling for therapeutic genome editing,” and the German Society for Gene Therapy listing described the work as showing for the first time that base editing could be therapeutically effective in this hyperinflammation model while also requiring careful genotoxicity evaluation. (cell.com) The article is listed in Cell Stem Cell with DOI 10.1016/j.stem.2026.04.014, and the named authors include Lei Lei, Masako M. Kaufmann, Jessica Lao and Gudrun Thoulass. The next step for readers who want the full methods is the journal version itself, where the comparative profiling and assay design are described in detail. (sciencedirect.com) (cell.com)